Hyperphosphataemia as a cardiovascular risk factor -- how to manage the problem

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Hyperphosphatemia is a significant cardiovascular risk factor in chronic kidney disease (CKD).
• Elevated phosphate levels contribute to vascular calcification through secondary hyperparathyroidism and direct calcium phosphate deposition.
• High phosphate levels are linked to increased mortality in CKD patients.

Purpose of the Study:

• To outline strategies for managing hyperphosphatemia in CKD patients.
• To emphasize the importance of controlling serum phosphate and calcium levels to mitigate cardiovascular risks.
• To discuss the role of diet, phosphate binders, and dialysis in phosphate management.

Main Methods:

• A multi-faceted approach including dietary modification, appropriate use of phosphate binders, and optimized dialysis.
• Maintaining serum phosphate <5 mg/dL and serum calcium <10 mg/dL to keep the calcium x phosphate product ≤50 mg²/dL².
• Utilizing non-calcium, non-aluminum phosphate binders like sevelamer hydrochloride.

Main Results:

• Effective phosphate control reduces the risk of vascular, valvular, and extraskeletal calcification.
• Sevelamer hydrochloride demonstrates efficacy and potential benefits on lipid profiles.
• Continuous ambulatory peritoneal dialysis may offer better phosphate control compared to hemodialysis.

Conclusions:

• A comprehensive management strategy is essential for controlling hyperphosphatemia in CKD.
• Optimizing dialysis parameters (duration and frequency) is crucial for phosphate removal.
• Careful selection and dosing of phosphate binders, particularly non-calcium-based ones, are vital.